|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UGT2A3 |
Gene summary for UGT2A3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UGT2A3 | Gene ID | 79799 |
| Gene name | UDP glucuronosyltransferase family 2 member A3 | |
| Gene Alias | UGT2A3 | |
| Cytomap | 4q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0006063 | UniProtAcc | Q6UWM9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79799 | UGT2A3 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.04e-03 | -3.34e-01 | 0.0155 |
| 79799 | UGT2A3 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.29e-02 | 3.53e-01 | -0.1954 |
| 79799 | UGT2A3 | HTA11_1391_2000001011 | Human | Colorectum | AD | 7.73e-03 | -3.42e-01 | -0.059 |
| 79799 | UGT2A3 | HTA11_866_3004761011 | Human | Colorectum | AD | 7.19e-06 | -3.79e-01 | 0.096 |
| 79799 | UGT2A3 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.15e-14 | -3.93e-01 | 0.0674 |
| 79799 | UGT2A3 | HTA11_6818_2000001021 | Human | Colorectum | AD | 2.79e-04 | -4.05e-01 | 0.0588 |
| 79799 | UGT2A3 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 7.23e-11 | -3.68e-01 | 0.294 |
| 79799 | UGT2A3 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.05e-15 | -3.94e-01 | 0.3859 |
| 79799 | UGT2A3 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 8.86e-04 | -2.88e-01 | 0.3005 |
| 79799 | UGT2A3 | A002-C-010 | Human | Colorectum | FAP | 3.52e-14 | -3.80e-01 | 0.242 |
| 79799 | UGT2A3 | A001-C-207 | Human | Colorectum | FAP | 3.03e-07 | -3.90e-01 | 0.1278 |
| 79799 | UGT2A3 | A015-C-203 | Human | Colorectum | FAP | 3.45e-11 | -2.83e-01 | -0.1294 |
| 79799 | UGT2A3 | A002-C-201 | Human | Colorectum | FAP | 3.19e-14 | -4.05e-01 | 0.0324 |
| 79799 | UGT2A3 | A002-C-203 | Human | Colorectum | FAP | 4.57e-16 | -3.93e-01 | 0.2786 |
| 79799 | UGT2A3 | A001-C-119 | Human | Colorectum | FAP | 6.53e-08 | -4.05e-01 | -0.1557 |
| 79799 | UGT2A3 | A001-C-108 | Human | Colorectum | FAP | 2.67e-20 | -4.05e-01 | -0.0272 |
| 79799 | UGT2A3 | A002-C-205 | Human | Colorectum | FAP | 8.31e-14 | -4.05e-01 | -0.1236 |
| 79799 | UGT2A3 | A001-C-104 | Human | Colorectum | FAP | 1.44e-14 | -3.64e-01 | 0.0184 |
| 79799 | UGT2A3 | A015-C-005 | Human | Colorectum | FAP | 1.52e-08 | -3.90e-01 | -0.0336 |
| 79799 | UGT2A3 | A015-C-006 | Human | Colorectum | FAP | 6.44e-09 | -4.05e-01 | -0.0994 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04976 | Colorectum | FAP | Bile secretion | 24/1404 | 89/8465 | 8.76e-03 | 3.21e-02 | 1.96e-02 | 24 |
| hsa049761 | Colorectum | FAP | Bile secretion | 24/1404 | 89/8465 | 8.76e-03 | 3.21e-02 | 1.96e-02 | 24 |
| hsa05207 | Colorectum | CRC | Chemical carcinogenesis - receptor activation | 42/1091 | 212/8465 | 2.62e-03 | 1.75e-02 | 1.19e-02 | 42 |
| hsa052071 | Colorectum | CRC | Chemical carcinogenesis - receptor activation | 42/1091 | 212/8465 | 2.62e-03 | 1.75e-02 | 1.19e-02 | 42 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UGT2A3 | SNV | Missense_Mutation | c.1468G>C | p.Asp490His | p.D490H | Q6UWM9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| UGT2A3 | SNV | Missense_Mutation | novel | c.782N>G | p.Asp261Gly | p.D261G | Q6UWM9 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
| UGT2A3 | SNV | Missense_Mutation | c.1073N>C | p.Asn358Thr | p.N358T | Q6UWM9 | protein_coding | deleterious(0.01) | probably_damaging(0.961) | TCGA-BI-A20A-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| UGT2A3 | SNV | Missense_Mutation | novel | c.419N>G | p.Glu140Gly | p.E140G | Q6UWM9 | protein_coding | tolerated(0.07) | benign(0.438) | TCGA-C5-A8ZZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | Cisplatin | SD |
| UGT2A3 | SNV | Missense_Mutation | c.682N>T | p.His228Tyr | p.H228Y | Q6UWM9 | protein_coding | deleterious(0.04) | possibly_damaging(0.558) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| UGT2A3 | SNV | Missense_Mutation | novel | c.1502N>G | p.Thr501Ser | p.T501S | Q6UWM9 | protein_coding | tolerated(0.15) | benign(0.078) | TCGA-MA-AA3X-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| UGT2A3 | SNV | Missense_Mutation | novel | c.1366G>A | p.Asp456Asn | p.D456N | Q6UWM9 | protein_coding | deleterious(0.01) | probably_damaging(0.981) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| UGT2A3 | SNV | Missense_Mutation | novel | c.1283G>C | p.Arg428Thr | p.R428T | Q6UWM9 | protein_coding | tolerated(0.09) | probably_damaging(0.932) | TCGA-AA-3971-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folinic | CR |
| UGT2A3 | SNV | Missense_Mutation | novel | c.65N>G | p.Phe22Cys | p.F22C | Q6UWM9 | protein_coding | tolerated(0.18) | possibly_damaging(0.784) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| UGT2A3 | SNV | Missense_Mutation | c.197N>G | p.Tyr66Cys | p.Y66C | Q6UWM9 | protein_coding | tolerated(0.14) | possibly_damaging(0.905) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |